181 drugs in 41 categories will be included in eighth batch of centralized drug purchase, covering 8 treatment categories including anti-infective drugs, cardio-cerebrovascular system drugs, blood and hematopoietic system drugs, and nervous system drugs.
More than 200 enterprises are expected to participate in the bidding for the eighth batch of national drug centralized purchase with the drugs covering eight treatment categories such as anti-infective drugs, cardio-cerebrovascular system drugs, blood and hematopoietic system drugs, and nervous system drugs.
Many of the varieties included in the centralized purchase are large varieties with market sales exceeding 1 billion yuan. According to statistics, 18 kinds of anti-infective drugs include many large antibiotic varieties. In addition, heparin products with a large market scale will be included in the centralized procurement for the first time and will be widely used in the treatment of a series of diseases including myocardial infarction, cardiovascular surgery and hemodialysis as anticoagulant and antithrombotic clinical drugs.
Since its establishment, the National Healthcare Security Administration has actively promoted the reform of purchasing drugs and high-value medical consumables with quantity, and squeezed the inflated price by exchanging quantity for price.
Up to now, China has carried out centralized purchase of drugs in 7 batches, with an average price reduction of more than 50%. The country has also carried out centralized purchase of consumables in three batches, with an average price reduction of more than 80%. These efforts have brought the price back to a reasonable level and reduced the drug consumption cost by more than 400 billion yuan.
